| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | - |
| Drug | Aflibercept |
| Brand | Zaltrap® |
| Indication | For the treatment of metastatic colorectal cancer in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) chemotherapy is indicated in adults with metastatic colorectal cancer (MCRC) that is resistant to or has progressed after an oxaliplatin-containing regimen. |
| Assessment Process | |
| Rapid review commissioned | 21/03/2013 |
| Rapid review completed | 10/04/2013 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 04/10/2013 |
| NCPE assessment completed | 12/02/2014 |
| NCPE assessment outcome | Reimbursement Recommended |
The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving.
